Roivant is discussing Phase 3 results for brepocitinib in non-infectious uveitis. For $ROIV the efficacy and safety detail in the slides is the part that matters for the tape, not the headline.
Phase 3 results for brepocitinib in non-infectious uveitis drive biotech catalyst relevance.
ROIV
$41.85
+1.60%
What changed
Phase 3 results for brepocitinib in non-infectious uveitis drive biotech catalyst relevance.
Why it matters
Phase 3 results for brepocitinib in non-infectious uveitis drive biotech catalyst relevance. — impact context not separately stored; see What changed.
← Dashboard
Oct 25, 2026 12:12 AM ET